A citation-based method for searching scientific literature

H Döhner, S Stilgenbauer, A Benner, E Leupolt, A Kröber, L Bullinger, K Döhner, M Bentz, P Lichter. N Engl J Med 2000
Times Cited: 2326







List of co-cited articles
869 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi,[...]. Blood 2018
551
42

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba,[...]. Blood 2014
340
32


Mutations driving CLL and their evolution in progression and relapse.
Dan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, Chip Stewart, Johannes G Reiter, Jasmin Bahlo, Sandra Kluth, Ivana Bozic, Mike Lawrence, Sebastian Böttcher,[...]. Nature 2015
595
26

TP53 mutation and survival in chronic lymphocytic leukemia.
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger,[...]. J Clin Oncol 2010
387
25

Non-coding recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Silvia Beà, Rafael Valdés-Mas, Neus Villamor, Jesús Gutiérrez-Abril, José I Martín-Subero, Marta Munar, Carlota Rubio-Pérez, Pedro Jares, Marta Aymerich,[...]. Nature 2015
526
24

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
T J Hamblin, Z Davis, A Gardiner, D G Oscier, F K Stevenson. Blood 1999
22

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Panagiotis Baliakas, Sabine Jeromin, Michalis Iskas, Anna Puiggros, Karla Plevova, Florence Nguyen-Khac, Zadie Davis, Gian Matteo Rigolin, Andrea Visentin, Aliki Xochelli,[...]. Blood 2019
82
26

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers,[...]. N Engl J Med 2018
413
22

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Kirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova,[...]. N Engl J Med 2019
337
22

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Tait D Shanafelt, Xin V Wang, Neil E Kay, Curtis A Hanson, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong C Zhang,[...]. N Engl J Med 2019
300
21

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Michael Hallek, Bruce D Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J Keating, Emili Montserrat, Kanti R Rai,[...]. Blood 2008
20

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R Furman, Jeff P Sharman, Steven E Coutre, Bruce D Cheson, John M Pagel, Peter Hillmen, Jacqueline C Barrientos, Andrew D Zelenetz, Thomas J Kipps, Ian Flinn,[...]. N Engl J Med 2014
19

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, John F Gerecitano, Thomas J Kipps, Mary Ann Anderson, Jennifer R Brown, Lori Gressick,[...]. N Engl J Med 2016
19

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
John C Byrd, Richard R Furman, Steven E Coutre, Ian W Flinn, Jan A Burger, Kristie A Blum, Barbara Grant, Jeff P Sharman, Morton Coleman, William G Wierda,[...]. N Engl J Med 2013
19

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Olga Samoilova, Jan Novak, Dina Ben-Yehuda,[...]. Lancet Oncol 2019
298
19

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Jan A Burger, Alessandra Tedeschi, Paul M Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L Bartlett, Jianyong Li,[...]. N Engl J Med 2015
875
18

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Susan O'Brien, Richard R Furman, Steven Coutre, Ian W Flinn, Jan A Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao,[...]. Blood 2018
253
18

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Jennifer A Woyach, Richard R Furman, Ta-Ming Liu, Hatice Gulcin Ozer, Marc Zapatka, Amy S Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne M Steggerda, Matthias Versele,[...]. N Engl J Med 2014
750
17

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel, Ian W Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett,[...]. Lancet 2020
173
17

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
J Malcikova, E Tausch, D Rossi, L A Sutton, T Soussi, T Zenz, A P Kater, C U Niemann, D Gonzalez, F Davi,[...]. Leukemia 2018
91
17

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Dan A Landau, Scott L Carter, Petar Stojanov, Aaron McKenna, Kristen Stevenson, Michael S Lawrence, Carrie Sougnez, Chip Stewart, Andrey Sivachenko, Lili Wang,[...]. Cell 2013
944
16

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
M Hallek, K Fischer, G Fingerle-Rowson, A M Fink, R Busch, J Mayer, M Hensel, G Hopfinger, G Hess, U von Grünhagen,[...]. Lancet 2010
15

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Xose S Puente, Magda Pinyol, Víctor Quesada, Laura Conde, Gonzalo R Ordóñez, Neus Villamor, Georgia Escaramis, Pedro Jares, Sílvia Beà, Marcos González-Díaz,[...]. Nature 2011
15

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer,[...]. Blood 2016
410
15

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna,[...]. N Engl J Med 2018
411
15

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, Sarah E M Herman, Xin Tian, Irina Maric, Diane C Arthur, Laura Wake, Stefania Pittaluga, Constance M Yuan,[...]. Blood 2017
186
15

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Carmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, Janine Altmüller, Holger Thiele, Jasmin Bahlo, Sandra Kluth, Giuliano Crispatzu, Marco Herling, Joanna Schiller,[...]. Blood 2016
85
16

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Davide Rossi, Silvia Rasi, Valeria Spina, Alessio Bruscaggin, Sara Monti, Carmela Ciardullo, Clara Deambrogi, Hossein Khiabanian, Roberto Serra, Francesco Bertoni,[...]. Blood 2013
325
14

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Peter Hillmen, Andy C Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J Yates, Rebecca Bishop, Rebecca Boucher, Donald MacDonald, Christopher Fegan, Alison McCaig,[...]. J Clin Oncol 2019
115
14

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Davide Rossi, Hossein Khiabanian, Valeria Spina, Carmela Ciardullo, Alessio Bruscaggin, Rosella Famà, Silvia Rasi, Sara Monti, Clara Deambrogi, Lorenzo De Paoli,[...]. Blood 2014
236
14

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
Davide Rossi, Silvia Rasi, Giulia Fabbri, Valeria Spina, Marco Fangazio, Francesco Forconi, Roberto Marasca, Luca Laurenti, Alessio Bruscaggin, Michaela Cerri,[...]. Blood 2012
315
13

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer,[...]. N Engl J Med 2014
980
13

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Davide Rossi, Michaela Cerri, Clara Deambrogi, Elisa Sozzi, Stefania Cresta, Silvia Rasi, Lorenzo De Paoli, Valeria Spina, Valter Gattei, Daniela Capello,[...]. Clin Cancer Res 2009
228
13

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Barbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, Raymonde Busch, Gabor Kovacs, Christian Maurer, Elisabeth Lange, Hubert Köppler, Michael Kiehl, Martin Sökler,[...]. Lancet Oncol 2016
365
13

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak,[...]. Lancet Oncol 2016
511
13

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Othman Al-Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna-Maria Fink, Sandra Robrecht, Olga Samoylova, Anna M Liberati, Javier Pinilla-Ibarz, Stephen Opat,[...]. Lancet Oncol 2020
84
15

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Ferran Nadeu, Julio Delgado, Cristina Royo, Tycho Baumann, Tatjana Stankovic, Magda Pinyol, Pedro Jares, Alba Navarro, David Martín-García, Sílvia Beà,[...]. Blood 2016
184
13


Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Philip A Thompson, Constantine S Tam, Susan M O'Brien, William G Wierda, Francesco Stingo, William Plunkett, Susan C Smith, Hagop M Kantarjian, Emil J Freireich, Michael J Keating. Blood 2016
320
12

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
Lili Wang, Michael S Lawrence, Youzhong Wan, Petar Stojanov, Carrie Sougnez, Kristen Stevenson, Lillian Werner, Andrey Sivachenko, David S DeLuca, Li Zhang,[...]. N Engl J Med 2011
784
12

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
12

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C Byrd, Jennifer R Brown, Susan O'Brien, Jacqueline C Barrientos, Neil E Kay, Nishitha M Reddy, Steven Coutre, Constantine S Tam, Stephen P Mulligan, Ulrich Jaeger,[...]. N Engl J Med 2014
12

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
R N Damle, T Wasil, F Fais, F Ghiotto, A Valetto, S L Allen, A Buchbinder, D Budman, K Dittmar, J Kolitz,[...]. Blood 1999
12

Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Nitin Jain, Michael Keating, Philip Thompson, Alessandra Ferrajoli, Jan Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Nathan Fowler, Tapan Kadia,[...]. N Engl J Med 2019
243
12

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
John C Byrd, Bonnie Harrington, Susan O'Brien, Jeffrey A Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G Wierda, Farrukh T Awan, Jennifer R Brown,[...]. N Engl J Med 2016
561
12

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna,[...]. J Clin Oncol 2020
70
17

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Mary Ann Anderson, Constantine Tam, Thomas E Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C S Huang,[...]. Blood 2017
107
11

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Philip A Thompson, Susan M O'Brien, William G Wierda, Alessandra Ferrajoli, Francesco Stingo, Susan C Smith, Jan A Burger, Zeev Estrov, Nitin Jain, Hagop M Kantarjian,[...]. Cancer 2015
170
11

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
Lijian Yu, Haesook T Kim, Siddha Kasar, Parul Benien, Wei Du, Kevin Hoang, Andrew Aw, Bethany Tesar, Reina Improgo, Stacey Fernandes,[...]. Clin Cancer Res 2017
60
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.